← Leaderboards
Arthur J. Moss
University Of Rochester
$13,356,209
Attributed
$14,471,248
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–17$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$14,471,248 · 8
By mechanism
R01$11,408,439 · 5
U01$3,048,018 · 1
M01$14,791 · 2
Top collaborators
- Robert S Kass4 shared
Most similar at University Of Rochester
Same institution · by research overlap
- Wojciech Zareba$21,736,071
- Richard T Moxley$13,171,275
- Jay Yang$8,324,911
- John D. Lueck$4,627,632
- Jean-Philippe Y Couderc$7,749,612
Others in their field
Top investigators on “Long Qt Syndrome”
- Dan M Roden · Vanderbilt University Medical Center$24,202,957
- Alfred L George · Vanderbilt University$22,284,132
- Gideon Koren · Brigham And Women'S Hospital$21,067,576
- Robert S Kass · Columbia University Health Sciences$10,862,791
- Charles R Sanders · Vanderbilt University$9,888,145
- Michael John Ackerman · Mayo Clinic Rochester$8,442,616
Research focus
Long Qt SyndromeClinical ResearchGenotypeHuman SubjectElectrocardiographyPhenotypeAdrenergic Beta-AntagonistsData ManagementFollow-UpSodium ChannelEnrollmentMossesGene MutationCardiacEventCalciumDisease /Disorder Proneness /RiskCardiovascular Disorder EpidemiologyAccountingFamily GeneticsGrantBasic ScienceBaseElectrocardiogram
Grant awards (32)
Clinical and Basic Science Studies in Long QT Syndrome Type 3$32,478
R01 · FY2017 · HL · contact PI
Clinical and Basic Science Studies in Long QT Syndrome Type 3$733,092
R01 · FY2016 · HL · contact PI
Clinical and Basic Science Studies in Long QT Syndrome Type 3$722,095
R01 · FY2015 · HL · contact PI
Late Sodium Current Blockade in High-Risk ICD Patients - DCC$743,021
U01 · FY2014 · HL · contact PI
Clinical and Basic Science Studies in Long QT Syndrome Type 3$742,413
R01 · FY2014 · HL · contact PI
Late Sodium Current Blockade in High-Risk ICD Patients - DCC$721,812
U01 · FY2013 · HL · contact PI
Late Sodium Current Blockade in High-Risk ICD Patients - DCC$752,744
U01 · FY2012 · HL · contact PI
Long QT Syndrome: Population, Genetic & Cardiac Studies$559,231
R01 · FY2011 · HL · contact PI
Late Sodium Current Blockade in High-Risk ICD Patients - DCC$830,441
U01 · FY2010 · HL · contact PI
Long QT Syndrome: Population, Genetic & Cardiac Studies$564,880
R01 · FY2010 · HL · contact PI
Long QT Syndrome: Population, Genetic & Cardiac Studies$562,008
R01 · FY2009 · HL · contact PI
Long QT Syndrome: Population, Genetic & Cardiac Studies$548,029
R01 · FY2008 · HL · contact PI
Long QT Syndrome: Population, Genetic & Cardiac Studies$564,070
R01 · FY2006 · HL · contact PI
Long QT Syndrome: Population, Genetic &Cardiac Studies$568,212
R01 · FY2005 · HL
Long QT Syndrome: Population, Genetic &Cardiac Studies$565,211
R01 · FY2004 · HL
Long QT Syndrome: Population, Genetic &Cardiac Studies$568,521
R01 · FY2003 · HL
Thrombogenic Factors and Recurrent Coronary Events$285,190
R01 · FY2003 · HL
Thrombogenic Factors and Recurrent Coronary Events$504,500
R01 · FY2002 · HL
LONG QT SYNDROME--POPULATION, GENETIC &CARDIAC STUDIES$490,208
R01 · FY2002 · HL
LONG QT SYNDROME--GENETIC STUDIES$407,390
R01 · FY2002 · HL
THERAPUTIC TRIAL IN PATIENTS WITH LQTS 3 GENE MUTATION$211,960
R01 · FY2002 · HL
CLINICAL PHARMACOLOGIC TARGETING W/ FLECAINIDE OF SCN5A GENE MUTATION$0
M01 · FY2002 · RR
Thrombogenic Factors and Recurrent Coronary Events$621,405
R01 · FY2001 · HL
LONG QT SYNDROME--POPULATION, GENETIC &CARDIAC STUDIES$479,982
R01 · FY2001 · HL
LONG QT SYNDROME--GENETIC STUDIES$402,021
R01 · FY2001 · HL
THERAPUTIC TRIAL IN PATIENTS WITH LQTS 3 GENE MUTATION$206,783
R01 · FY2001 · HL
LONG QT SYNDROME--POPULATION, GENETIC &CARDIAC STUDIES$468,935
R01 · FY2000 · HL
LONG QT SYNDROME--GENETIC STUDIES$392,076
R01 · FY2000 · HL
THERAPUTIC TRIAL IN PATIENTS WITH LQTS 3 GENE MUTATION$201,389
R01 · FY2000 · HL
THERAPEUTIC TRIAL IN PATIENTS W/ LQTS 3 GENE MUTATION$14,791
M01 · FY2000 · RR
THERAPUTIC TRIAL IN PATIENTS WITH LQTS 3 GENE MUTATION$6,360
R01 · FY2000 · HL
CLINICAL PHARMACOLOGIC TARGETING W/ FLECAINIDE OF SCN5A GENE MUTATION$0
M01 · FY2000 · RR